At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
Naltrexone +1 moredrug
Likely dose
Naltrexone 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment
In Brief
A Phase 2 clinical trial evaluating Naltrexone and Placebo for Hazardous Drinking and Cigarette Smoking. Completed, enrolled 150 participants across 1 site.
Detailed Summary
To test whether naltrexone compared to placebo can reduce heavy drinking and improve smoking cessation outcomes in heavy drinkers seeking smoking cessation treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHazardous Drinking, Cigarette Smoking
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartOct 2009
Primary CompletionNov 2015
Study CompletionDec 2015
TodayJul 2026
First PostedJul 14, 2009
Enrollment StartOct 1, 2009
Primary CompletionNov 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 17.0 years ago
Interventions
Naltrexonedrug
Daily 50 mg naltrexone
Placebodrug
Matched naltrexone placebo